Bronchiectasis Adult
Conditions
Keywords
bronchiectasis, lung function, quality of life, mucus properties
Brief summary
Although relatively common, bronchiectasis is considered an orphan disease as there is little evidence for adequate treatment, most of the therapeutic options are extrapolated from studies with patients with chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF). Inhaled bronchodilators and corticosteroids should be used as a therapeutic test and maintained if there is improvement of symptoms or lung function. There is no evidence to justify the use of mucolytic agents for these patients. The treatment with greater evidence is the use of macrolides, especially azithromycin. A meta-analysis published in 2014 showed that there was a reduction in the number of exacerbations, an improvement in the quality of life and a reduction in the decrease in FEV1. However, studies have shown conflicting results regarding quality of life and pulmonary function. Roflumilast is a phosphodiesterase-4 inhibitor with an anti-inflammatory effect in vitro and in vivo due to the inhibition of cyclic adenosine monopostat breakdown (cAMP) to its inactive phosphodiesterase form. As this enzyme is expressed in high concentrations in leukocytes and other inflammatory cells responsible for the pathogenesis of pulmonary diseases such as COPD, it has been studied and used for this disease. COPD is characterized by a chronic inflammatory process of the airways, predominantly neutrophils and high levels of proinflammatory cytokines related to this cell, such as interleukin-8, neutrophil elastase, tumor necrosis factor (TNF) alpha and E-selectin. The REACT study showed that roflumilast prevents moderate and severe infectious exacerbations in addition to improved lung function in patients with COPD who continue to exacerbate despite the use of combined bronchodilator and inhaled corticosteroid therapy. Since bronchiectasis and COPD are chronic inflammatory diseases, they present similar inflammatory processes, with neutrophil as the main inflammatory cell, it is expected that the use of roflumilast also has an anti-inflammatory effect in bronchiectasis. In addition, since bronchiectasis is a disease with poor evidence for pharmacological treatment, it is necessary to search for new therapeutic possibilities.
Interventions
DRUGRoflumilast
500Mcg Tab, once daily
DRUGPlacebo oral tablet
once daily
Sponsors
Fundação de Amparo à Pesquisa do Estado de São Paulo
University of Sao Paulo General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Placebo-controlled
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years; * Diagnosis of bronchiectasis by chest tomography; * FEV1 \<60% of predicted; * History of chronic bronchitis (chronic cough and sputum for at least 3 months in the last 2 years); * 2 or more infectious exacerbations in the last year (defined as worsening of cough and / or dyspnoea and / or decreased general condition, increased quantity and purulence of sputum that required systemic antibiotic use (oral or intravenous).
Exclusion criteria
* Hemoptysis in the last 6 months (significance at the discretion of the investigator); * Current or prior smoking if \> 10 pack-years; * FEV1 \< 30% of predicted; * Known allergy to roflumilast; * Pulmonary exacerbation present or occurring in the last 4 weeks; * Child B or C cirrhosis; * Active cancer (except basal cell carcinoma); * Severe heart failure; * Depression associated with suicidal ideation; * Pregnancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life questionnaire | 12 weeks | To evaluate the impact of roflumilast on the quality of life of patients with bronchiectasis through the Saint George Respiratory Questionnaire (SGRQ). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Other tools for quality of life | 12 weeks | To evaluate the impact of roflumilast on quality of life using the questionnaires Leicester, Quality of Life Questionnaire-Bronchiectasis (QOL-B) Bronchiectasis Health Questionnaire (BHQ) |
| Dyspnea | 12 weeks | To evaluate the impact of roflumilast on severity of dyspnea as measured by the COPD Assessment Test (CAT) |
| Lung function | 12 weeks | To evaluate the impact of roflumilast on lung function measured by forced expiratory volume at one second (FEV1) |
| Adverse events | 12 weeks | To evaluate the safety of roflumilast assessed through the incidence of adverse events |
Countries
Brazil
Contacts
Primary ContactRodrigo A Athanazio, MD, PhD
Outcome results
None listed